Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53

Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53

Saved in:

Bibliographic Details
Main Authors:	Xiangbing Meng, Don S. Dizon, Shujie Yang, Xinjun Wang, Danlin Zhu, Kristina W. Thiel, Kimberly K. Leslie
Format:	Article
Language:	English
Published:	Wiley 2013-01-01
Series:	Obstetrics and Gynecology International
Online Access:	http://dx.doi.org/10.1155/2013/828165
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
by: Sara Costa-Cabral, et al.
Published: (2016-01-01)

Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancers
by: Roman M. Chabanon, et al.
Published: (2025-07-01)

Targeting synthetic lethality in colorectal cancer
by: Pingting Chen, et al.
Published: (2025-07-01)

Synthetic lethality in cancer: a protocol for scoping review of gene interactions from synthetic lethal screens and functional studies
by: Raashi Chauhan, et al.
Published: (2025-04-01)

Mslar: Microbial synthetic lethal and rescue database.
by: Sen-Bin Zhu, et al.
Published: (2023-06-01)

Genome‐scale gene/reaction essentiality and synthetic lethality analysis
by: Patrick F Suthers, et al.
Published: (2009-08-01)

Mutations in tumor signaling, metastases, and synthetic lethality establish distinct patterns.
by: Bengi Ruken Yavuz, et al.
Published: (2025-08-01)

MYC and the unfolded protein response in cancer: synthetic lethal partners in crime?
by: Tingting Zhang, et al.
Published: (2020-04-01)

Discovery of Drugs Targeting Mutant p53 and Progress in Nano-Enabled Therapeutic Strategy for p53-Mutated Cancers
by: Na Zhang, et al.
Published: (2025-05-01)

Bypassing the guardian: regulated cell death pathways in p53-mutant cancers
by: Jonathan Y. Chung, et al.
Published: (2025-06-01)

Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults
by: Ethan J. Harris, et al.
Published: (2025-08-01)

Glutathione reductase underlies the stability of mutant p53 by antagonizing protein glutathionylation
by: Liansheng Wang, et al.
Published: (2025-04-01)

A systematic analysis of the network of lncRNAs and mRNAs regulated by TP53 and TP53 mutants with hotspot mutations
by: Hong Chen, et al.
Published: (2025-07-01)

Venetoclax confers synthetic lethality to chidamide in preclinical models with transformed follicular lymphoma
by: Mengya Zhong, et al.
Published: (2025-05-01)

Mutant p53 induces SH3BGRL expression to promote cell engulfment
by: Lobsang Dolma, et al.
Published: (2025-07-01)

PRIMA-1MET Inhibits Growth of Mouse Tumors Carrying Mutant p53
by: Nicole Zache, et al.
Published: (2008-01-01)

CHEK1 is a synthetic lethal interactor of FBXO7 in colonic epithelial cells
by: Tooba Razi, et al.
Published: (2025-09-01)

Z-scores outperform similar methods for analyzing CRISPR paralog synthetic lethality screens
by: Juihsuan Chou, et al.
Published: (2025-07-01)

NAMPT haploinsufficiency is a collateral lethal therapeutic vulnerability in high-risk myeloid malignancies with TP53 inactivation
by: Madhavi D. Senagolage, et al.
Published: (2025-08-01)

Predicting p53 Status in IDH‐Mutant Gliomas Using MRI‐Based Radiomic Model
by: Jiamin Li, et al.
Published: (2025-08-01)

Tauopathic changes in the striatum of A53T α-synuclein mutant mouse model of Parkinson's disease.
by: Jonathan Wills, et al.
Published: (2011-03-01)

Cost-effectiveness of chemotherapy in advanced and recurrent endometrial cancer
by: Katsuaki Inami
Published: (2025-06-01)

Activation of LXRβ inhibits tumor respiration and is synthetically lethal with Bcl‐xL inhibition
by: Trang Thi Thu Nguyen, et al.
Published: (2019-08-01)

In silico study of the potential of curcumin and its derivatives for increasing wild-type p53 expression and improving the function of p53 mutant R273H
by: Sarah Ika Nainggolan, et al.
Published: (2025-03-01)

Identifying and exploiting combinatorial synthetic lethality by characterizing adaptive kinome rewiring of EGFRvIII-driven glioblastoma
by: Benjamin Lin, et al.
Published: (2025-06-01)

A 'synthetic-sickness' screen for senescence re-engagement targets in mutant cancer backgrounds.
by: Claire J Cairney, et al.
Published: (2017-08-01)

Rezatapopt: A promising small-molecule “refolder” specific for TP53Y220C mutant tumors
by: Kostas A. Papavassiliou, et al.
Published: (2025-09-01)

Synthetic lethality between VPS4A and VPS4B triggers an inflammatory response in colorectal cancer
by: Ewelina Szymańska, et al.
Published: (2020-01-01)

Calibrating Transcriptional Activity Using Constitutive Synthetic Promoters in Mutants for Global Regulators in Escherichia coli
by: Ananda Sanches-Medeiros, et al.
Published: (2018-01-01)

A thiol‐bound drug reservoir enhances APR‐246‐induced mutant p53 tumor cell death
by: Sophia Ceder, et al.
Published: (2020-12-01)

Perspectives on cancer therapy—synthetic lethal precision medicine strategies, molecular mechanisms, therapeutic targets and current technical challenges
by: Shixuan Peng, et al.
Published: (2025-04-01)

Comprehensive assessment of the acute lethal, risk level, and sub-lethal effects of four insecticides on Trichogramma ostriniae
by: Wenya Zhu, et al.
Published: (2025-01-01)

Pembrolizumab plus chemotherapy in advanced endometrial cancer: a cost-effectiveness analysis
by: Xinqiang Zhao, et al.
Published: (2025-06-01)

Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML
by: David A. Sallman, et al.
Published: (2025-07-01)

Targeting MDM2 homodimer and heterodimer disruption with DRx-098D in TP53 wild-type and mutant cancer cells
by: Sean F. Cooke, et al.
Published: (2025-09-01)

CEP-1, the Caenorhabditis elegans p53 homolog, mediates opposing longevity outcomes in mitochondrial electron transport chain mutants.
by: Aiswarya Baruah, et al.
Published: (2014-02-01)

Achievements and prospects of therapy for non-atypical endometrial hyperplasia in reproductive-aged women
by: D.A. Khaskhachikh
Published: (2024-12-01)

The impact of mismatch repair (MMR), p53, and LCAM-1 immunohistochemical expression on prognosis in low-risk endometrial cancer
by: Şener Gezer, et al.
Published: (2025-06-01)

The Estrogen Receptor Joins Other Cancer Biomarkers as a Predictor of Outcome
by: Kimberly K. Leslie, et al.
Published: (2013-01-01)

Berberine hydrochloride inhibits the proliferation and metastasis of p53 mutant gallbladder Cancer cells by regulating the IL6/STAT3 pathway
by: Huan Zhang, et al.
Published: (2025-07-01)